141 related articles for article (PubMed ID: 30292087)
1. Antipsychotics and cardiovascular risk: A case/non-case study.
Arias LHM; Fadrique RS; García SP; Gil MS; Lobato CT; Ortega PG
Psychiatry Res; 2018 Dec; 270():341-347. PubMed ID: 30292087
[TBL] [Abstract][Full Text] [Related]
2. Risk excess of mortality and use of antipsychotics: a case-noncase study.
Martín Arias LH; Treceño Lobato C; Pérez García S; Sáinz Gil M; Sanz Fadrique R; García Ortega P
Int Clin Psychopharmacol; 2017 Jan; 32(1):1-5. PubMed ID: 27602888
[TBL] [Abstract][Full Text] [Related]
3. [Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database].
Rochoy M; Auffret M; Béné J; Gautier S;
Rev Epidemiol Sante Publique; 2017 Feb; 65(1):1-8. PubMed ID: 27988172
[TBL] [Abstract][Full Text] [Related]
4. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
5. Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study.
Martin Arias LH; Martin Gonzalez A; Sanz Fadrique R; Salgueiro E; Sainz M
Int J Clin Pharm; 2018 Aug; 40(4):928-935. PubMed ID: 30066292
[TBL] [Abstract][Full Text] [Related]
6. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
[TBL] [Abstract][Full Text] [Related]
7. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk factors in chronic treatment with antipsychotic agents used in primary care.
Mundet-Tudurí X; Iglesias-Rodal M; Olmos-Domínguez C; Bernard-Antoranz ML; Fernández-San Martín MI; Amado-Guirado E
Rev Neurol; 2013 Dec; 57(11):495-503. PubMed ID: 24265143
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
[TBL] [Abstract][Full Text] [Related]
10. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
Glassman AH
J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.
Poluzzi E; Raschi E; Koci A; Moretti U; Spina E; Behr ER; Sturkenboom M; De Ponti F
Drug Saf; 2013 Jun; 36(6):467-79. PubMed ID: 23553446
[TBL] [Abstract][Full Text] [Related]
12. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
[TBL] [Abstract][Full Text] [Related]
13. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database.
Pugi A; Bonaiuti R; Maggini V; Moschini M; Tuccori M; Leone R; Rossi M; Motola D; Piccinni C; Ferrazin F; Sottosanti L; Mugelli A; Vannacci A; Lapi F
Am J Health Syst Pharm; 2013 Jun; 70(12):1039-46. PubMed ID: 23719881
[TBL] [Abstract][Full Text] [Related]
15. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.
Raschi E; Poluzzi E; Godman B; Koci A; Moretti U; Kalaba M; Bennie M; Barbui C; Wettermark B; Sturkenboom M; De Ponti F
PLoS One; 2013; 8(11):e81208. PubMed ID: 24278396
[TBL] [Abstract][Full Text] [Related]
16. Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Cepaityte D; Siafis S; Egberts T; Leucht S; Kouvelas D; Papazisis G
Schizophr Bull; 2021 Apr; 47(3):672-681. PubMed ID: 33289848
[TBL] [Abstract][Full Text] [Related]
17. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F
Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
[TBL] [Abstract][Full Text] [Related]
19. Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022.
Storck W; de Laportalière TT; Yrondi A; Javelot H; Berna F; Montastruc F
Psychopharmacology (Berl); 2024 Jun; 241(6):1205-1212. PubMed ID: 38376511
[TBL] [Abstract][Full Text] [Related]
20. Cataracts and statins. A disproportionality analysis using data from VigiBase.
Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]